NUVATION BIO INC (NUVB) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:NUVB • US67080N1019

5.7 USD
+0.08 (+1.42%)
At close: Feb 6, 2026
5.68 USD
-0.02 (-0.35%)
After Hours: 2/6/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall NUVB gets a fundamental rating of 2 out of 10. We evaluated NUVB against 191 industry peers in the Pharmaceuticals industry. NUVB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NUVB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NUVB has reported negative net income.
  • In the past year NUVB has reported a negative cash flow from operations.
  • NUVB had negative earnings in each of the past 5 years.
  • In the past 5 years NUVB always reported negative operating cash flow.
NUVB Yearly Net Income VS EBIT VS OCF VS FCFNUVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

  • NUVB has a Return On Assets of -36.15%. This is comparable to the rest of the industry: NUVB outperforms 46.07% of its industry peers.
  • With a Return On Equity value of -66.74%, NUVB perfoms like the industry average, outperforming 45.03% of the companies in the same industry.
Industry RankSector Rank
ROA -36.15%
ROE -66.74%
ROIC N/A
ROA(3y)-44.25%
ROA(5y)-34.58%
ROE(3y)-50.3%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
NUVB Yearly ROA, ROE, ROICNUVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • NUVB has a better Gross Margin (54.26%) than 66.49% of its industry peers.
  • The Profit Margin and Operating Margin are not available for NUVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVB Yearly Profit, Operating, Gross MarginsNUVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • NUVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NUVB has more shares outstanding than it did 1 year ago.
  • NUVB has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, NUVB has a worse debt to assets ratio.
NUVB Yearly Shares OutstandingNUVB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
NUVB Yearly Total Debt VS Total AssetsNUVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • NUVB has an Altman-Z score of 1.47. This is a bad value and indicates that NUVB is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of NUVB (1.47) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.61 indicates that NUVB is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.61, NUVB is doing worse than 66.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z 1.47
ROIC/WACCN/A
WACC9.42%
NUVB Yearly LT Debt VS Equity VS FCFNUVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • NUVB has a Current Ratio of 8.48. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 8.48, NUVB is doing good in the industry, outperforming 74.87% of the companies in the same industry.
  • A Quick Ratio of 8.39 indicates that NUVB has no problem at all paying its short term obligations.
  • NUVB has a Quick ratio of 8.39. This is in the better half of the industry: NUVB outperforms 75.39% of its industry peers.
Industry RankSector Rank
Current Ratio 8.48
Quick Ratio 8.39
NUVB Yearly Current Assets VS Current LiabilitesNUVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for NUVB have decreased strongly by -48.84% in the last year.
  • Looking at the last year, NUVB shows a very strong growth in Revenue. The Revenue has grown by 1137.19%.
EPS 1Y (TTM)-48.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)1137.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1704.68%

3.2 Future

  • The Earnings Per Share is expected to grow by 53.75% on average over the next years. This is a very strong growth
  • NUVB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 202.98% yearly.
EPS Next Y-16.6%
EPS Next 2Y0.45%
EPS Next 3Y18.24%
EPS Next 5Y53.75%
Revenue Next Year2392.77%
Revenue Next 2Y760.39%
Revenue Next 3Y423.77%
Revenue Next 5Y202.98%

3.3 Evolution

NUVB Yearly Revenue VS EstimatesNUVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
NUVB Yearly EPS VS EstimatesNUVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NUVB. In the last year negative earnings were reported.
  • Also next year NUVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVB Price Earnings VS Forward Price EarningsNUVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVB Per share dataNUVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NUVB's earnings are expected to grow with 18.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.45%
EPS Next 3Y18.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NUVB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NUVATION BIO INC

NYSE:NUVB (2/6/2026, 8:04:00 PM)

After market: 5.68 -0.02 (-0.35%)

5.7

+0.08 (+1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03
Earnings (Next)03-04
Inst Owners65.36%
Inst Owner Change-0.51%
Ins Owners17.92%
Ins Owner Change0%
Market Cap1.95B
Revenue(TTM)26.75M
Net Income(TTM)-217.48M
Analysts83.75
Price Target11.42 (100.35%)
Short Float %17.46%
Short Ratio6.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.93%
Min EPS beat(2)0.88%
Max EPS beat(2)6.98%
EPS beat(4)3
Avg EPS beat(4)0.55%
Min EPS beat(4)-6.56%
Max EPS beat(4)6.98%
EPS beat(8)5
Avg EPS beat(8)-11.26%
EPS beat(12)9
Avg EPS beat(12)-2.73%
EPS beat(16)12
Avg EPS beat(16)-0.14%
Revenue beat(2)2
Avg Revenue beat(2)660.6%
Min Revenue beat(2)94.49%
Max Revenue beat(2)1226.72%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.23%
PT rev (3m)28.52%
EPS NQ rev (1m)6.67%
EPS NQ rev (3m)37.31%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)9.02%
Revenue NQ rev (1m)7.25%
Revenue NQ rev (3m)132.67%
Revenue NY rev (1m)-1.25%
Revenue NY rev (3m)82.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 73.06
P/FCF N/A
P/OCF N/A
P/B 6
P/tB 6.22
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.08
BVpS0.95
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.15%
ROE -66.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.26%
FCFM N/A
ROA(3y)-44.25%
ROA(5y)-34.58%
ROE(3y)-50.3%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 581.54%
Cap/Sales 30.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.48
Quick Ratio 8.39
Altman-Z 1.47
F-Score4
WACC9.42%
ROIC/WACCN/A
Cap/Depr(3y)79.93%
Cap/Depr(5y)109.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y-16.6%
EPS Next 2Y0.45%
EPS Next 3Y18.24%
EPS Next 5Y53.75%
Revenue 1Y (TTM)1137.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1704.68%
Revenue Next Year2392.77%
Revenue Next 2Y760.39%
Revenue Next 3Y423.77%
Revenue Next 5Y202.98%
EBIT growth 1Y-73.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-186.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-174.8%
OCF growth 3YN/A
OCF growth 5YN/A

NUVATION BIO INC / NUVB FAQ

What is the ChartMill fundamental rating of NUVATION BIO INC (NUVB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NUVB.


Can you provide the valuation status for NUVATION BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to NUVATION BIO INC (NUVB). This can be considered as Overvalued.


How profitable is NUVATION BIO INC (NUVB) stock?

NUVATION BIO INC (NUVB) has a profitability rating of 1 / 10.